NCT05353439 2026-03-18
Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
Clinical Trials
96 trialsNCT05990738 2026-03-17
DAREONâ„¢-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy
Boehringer Ingelheim
Phase 1 Active not recruiting
NCT07194044 2026-03-16
METTSEO
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Recruiting
NCT05421897 2026-01-29
RAPID
Children's Hospital Los Angeles
Phase 1 Active not recruiting
NCT01175356 2026-01-23
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
Children's Oncology Group
Phase 1 Completed
NCT06930755 2026-01-21
Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer
Nerviano Medical Sciences
Phase 1 Recruiting
NCT05521984 2025-12-08
Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)
Washington University School of Medicine
Phase 1 Recruiting
NCT05429502 2025-10-10
Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors
Novartis
Phase 1 Terminated
NCT03107988 2025-09-15
NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)
New Approaches to Neuroblastoma Therapy Consortium
Phase 1 Completed
NCT04106219 2025-07-23
A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma
Eli Lilly and Company
Phase 1 Active not recruiting
NCT04239092 2025-07-17
9-ING-41 in Pediatric Patients With Refractory Malignancies.
Actuate Therapeutics Inc.
Phase 1 Terminated
NCT00308165 2025-06-27
Topotecan by Intracerebral Clysis for Recurrent Primary Malignant Brain Tumors
Columbia University
Phase 1 Completed
NCT02354547 2025-05-30
A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors
SynerGene Therapeutics, Inc.
Phase 1 Suspended
NCT05101551 2025-05-29
PARPAML
Stanford University
Phase 1 Recruiting
NCT00638898 2025-03-20
Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor
City of Hope Medical Center
Phase 1 Completed
NCT04514497 2025-03-06
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT02030964 2025-02-17
DFMO
New Approaches to Neuroblastoma Therapy Consortium
Phase 1 Completed
NCT02298348 2025-02-17
N2013-02
New Approaches to Neuroblastoma Therapy Consortium
Phase 1 Active not recruiting
NCT01798004 2024-07-15
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Children's Oncology Group
Phase 1 Completed
NCT01606878 2024-01-05
Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Children's Oncology Group
Phase 1 Completed
NCT02649673 2023-12-05
LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies
SCRI Development Innovations, LLC
Phase 1 Terminated
NCT03600649 2023-11-21
Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas
Salarius Pharmaceuticals, LLC
Phase 1 Unknown
NCT00856037 2023-09-26
Topotecan Hydrochloride and Doxorubicin Hydrochloride in Treating Relapsed or Refractory Small Cell Lung Cancer
University of Nebraska
Phase 1 Completed
NCT04661852 2023-02-15
Cabozantinib With Topotecan-Cyclophosphamide
Dana-Farber Cancer Institute
Phase 1 Completed
NCT04022876 2022-10-10
A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)
Aileron Therapeutics, Inc.
Phase 1 Terminated
NCT03154996 2022-07-05
Chronic Convection Enhanced Delivery of Topotecan
Columbia University
Phase 1 Completed
NCT03987685 2022-02-16
Evaluate Oral Topotecan With HM30181A Monotherapy in Patients With Advanced Malignancies
Athenex, Inc.
Phase 1 Completed
NCT03227016 2021-01-27
Study in Patients With SCLC of Veliparib in Combination With Topotecan
Central European Society for Anticancer Drug Research
Phase 1 Unknown
NCT02390843 2020-04-03
AflacST1402
Emory University
Phase 1 Completed
NCT00005792 2019-11-08
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT00652691 2019-04-08
Topotecan, High-Dose Cyclophosphamide, Carboplatin, and an Autologous Peripheral Blood Cell Transplant in Treating Patients With Recurrent Ovarian Cancer or Primary Peritoneal Cancer
Mayo Clinic
Phase 1 Completed
NCT03763123 2018-12-04
A Phase 1b Study of Sevacizumab in Combination With Chemotherapy in Chinese Patients With Platinum-Resistant Recurrent Ovarian Cancer.
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1 Unknown
NCT00287963 2018-05-17
Topotecan and Vinorelbine in Treating Patients With Recurrent Lung Cancer
Medical University of South Carolina
Phase 1 Completed
NCT00287911 2017-12-02
Topotecan, Cisplatin, and Radiation Therapy in Treating Patients With Advanced Cervical Cancer
Masonic Cancer Center, University of Minnesota
Phase 1 Completed
NCT00361803 2017-11-17
Topotecan Pharmacokinetic Characterization Study
GlaxoSmithKline
Phase 1 Completed
NCT00158886 2017-11-14
Oral Topotecan As A Radiosensitizing Agent In Rectal Cancer
GlaxoSmithKline
Phase 1 Terminated
NCT00259935 2017-11-14
A Study To Determine If Two Different Versions Of Topotecan Have The Same Potency In Patients With Advanced Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT00483860 2017-11-13
A Phase I Topotecan Study in Subjects With Cancer and Impaired Renal Function
GlaxoSmithKline
Phase 1 Completed
NCT00732420 2017-11-13
Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT00541359 2017-08-09
Bortezomib and Topotecan Hydrochloride in Treating Patients With Advanced Solid Tumors
City of Hope Medical Center
Phase 1 Completed
NCT00117013 2017-07-02
A Pilot Trial of Oral Topotecan for the Treatment of Refractory Advanced Solid Neoplasms Expressing HIF-1a
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00553189 2017-07-02
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT01670175 2017-06-21
Sirolimus With Cyclophosphamide and Topotecan for Pediatric/Adolescent Relapsed and Refractory Solid Tumors
University of California, San Francisco
Phase 1 Completed
NCT00046111 2017-05-30
A Bioequivalence Study of Two Oral Formulations of Topotecan in Patients With Advanced Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT00800345 2017-03-28
Phase I Trial of Oral Metronomic Topotecan and Oral Pazopanib to Treat Recurrent/Persistent Gynecologic Tumors
Vector Oncology
Phase 1 Completed
NCT00045175 2016-06-23
UCN-01 and Topotecan in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
University Health Network, Toronto
Phase 1 Completed
NCT00422682 2016-06-10
A Study Evaluating BSI-201 in Combination With Chemotherapeutic Regimens in Subjects With Advanced Solid Tumors
Sanofi
Phase 1 Completed
NCT01683149 2016-03-04
Sorafenib and Topotecan in Refractory/Recurrent Pediatric Malignancies
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT00466232 2015-12-16
Phase I Study of Weekly Topotecan in Combination With Sorafenib in Treatment of Relapsed Small Cell Lung Cancer
HealthPartners Institute
Phase 1 Completed
NCT00682279 2015-04-17
A Phase I Study Of Oral Topotecan And Lapatinib In Subjects With Advanced Solid Tumors
GlaxoSmithKline
Phase 1 Withdrawn